Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trulicity Monotherapy vs Placebo and Liraglutide in Japanese T2D Patients
NCT01558271Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Primary completion
- Oct 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Mar 2012; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01558271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01558271.